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A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific
antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the
toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.
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Antibody-directed enzyme-prodrug therapy (ADEPT) utilises
antibody–enzyme constructs for targeted enzyme delivery to
tumours and subsequent localised activation of a prodrug. Its
potential has been demonstrated in phase I studies (Webley et al,
2001).
Monoclonal antibody A33 recognises a cell-surface antigen that
is expressed on B95% of colon cancers (Garin-Chesa et al, 1996).
In clinical trials, radiolabelled A33 localised specifically to colon
cancer cells, where it was retained for several weeks while clearing
within days from normal colon (Welt et al, 1996).
Cytosine deaminase (CD) converts 5-fluorocytosine (5-FC) into
5-fluorouracil (5-FU) and has been empolyed in ADEPT (Wallace
et al, 1994).
Recombinant fusion constructs should overcome the problems
of chemical antibody–enzyme conjugation including inhomoge-
neous products and large protein size. Several recombinant
constructs based on F(ab) and F(ab0)2 fragments have been
described. Constructs based on single-chain variable fragments
(scFv) may have favourable diffusion characteristics in solid
tumours, but few descriptions of this approach have been
published (Bhatia et al, 2000). Here, we report on a new ADEPT
concept based on the A33 antigen and recombinant scFv–CD
constructs.
MATERIALS AND METHODS
A33scFv (Rader et al, 2000) and CD (Austin and Huber, 1993)
cDNA were PCR-amplified. Primers based on the published
sequences were designed to remove start or stop codons and to
add flanking restriction sites so that the DNA could be inserted
into the pET 25 expression vector (Novagen, Madison, WI, USA)
both directly and downstream of the inserted A33scFv DNA, so
that the orientation of the fusion protein was 50-A33scFv-CD-30
(vector map available upon request).
A33scFv, CD, and A33scFv-CD and the control construct
A33scFv-GFP were expressed by a T7-RNA polymerase-controlled
bacterial system using BL21 Escherichia coli lDE3 lysogens
(Novagen, Madison, WI, USA) at 371C with IPTG induction at
an OD600nm of 0.5–0.7. Inclusion bodies were retrieved from cell
pellets and solubilised using BugBustert reagent with 0.3mlml
 1
Benzonase and Novagen Refolding Kit (both: Novagen, Madison,
WI, USA) according to the manufacturer’s instructions. Utilizing a
C-terminal histidin tag, the protein was purified on sepharose-
bound cobalt (Clontech) with imidazole elution.
Plasmon surface resonance assays were performed as described
(Catimel et al, 1997) with A33 antigen-coated Biosensor chips.
After 400s, sample flow was replaced by buffer solution. The
relative refraction at 600s was compared with buffer flow and
positive controls.
Catalytic activity of cytosine deaminase was determined as
described (Austin and Huber, 1993).
For cytotoxicity assays, LIM 1215 or HT 29 tumour cells
(Ludwig Institute for Cancer Research cell bank) were incubated
on 96-well plates to reach 25–33% surface density. Fusion protein
or control was added for 60min, preceded by 90min of incubation
with ‘‘A33scFv-GFP’’ or hu3S193 IgG (1mg ml
 1) in blocking
experiments. After washing, cells were incubated with prodrug or
control for 48h, washed and grown in medium for 72h, followed
by 3h in 0.5mg ml
 1 MTT-solution, DMSO-lysis and photometry
at 595nm.
RESULTS
Protein expression and activity
Fusion proteins were expressed as inclusion bodies with a final
culture yield of about 100mgl
 1. With metal affinity chromato-
graphy purity was 495% by SDS–PAGE.
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sCalculated from the molar extinction coefficient of 1.038mM
 1
for 5-FU, the catalytic activity was 2.5mM min
 1 for recombinant
CD and 0.8mMmin
 1 for the A33scFv–CD fusion protein.
In surface plasmon resonance, all A33 preparations, but not the
3S193 control, displayed typical association and dissociation
curves. Univalent A33scFv showed about half the binding activity
of divalent of huA33 IgG (Figure 1), and A33scFv–CD had slightly
less binding activity than A33scFv.
ADEPT system in vitro
The antigen binding and enzymatic activity of the A33scFv–CD
fusion protein was assessed in cytotoxicity assays using complete
ADEPT system. The cytotoxicities of 5-FC and 5-FU showed no
significant differences between the colon cancer cell lines LIM1215
(A33+) and HT29 (A33–) with an IC50 of about 30mM for 5-FC
and 0.3–0.03mM for 5-FU (Po 0.05 for 5-FC vs 5-FU, no
significant difference between cell lines).
The complete ADEPT system was tested by incubating these two
cell lines first with a serial dilution of A33scFv–CD and then, after
washing, with the 5-FC prodrug at a fixed concentration. In this
assay, crude and purified A33scFv–CD had a dose-dependant
cytotoxic effect on A33-positive LIM1215 cells (IC50B150ngml
 1),
but not on A33-negative cells (P¼0.001 in Wilcoxon rank test). No
cytotoxicity was observed with the A33scFv–GFP control
(Figure 2).
Without subsequent prodrug incubation, even the highest
concentration of fusion protein tested had no cytotoxic effect on
A33-positive LIM1215 cells (Figure 3). When binding of A33scFv–
CD was blocked by preincubation with ‘‘A33scFv-GFP’’, subse-
quent 5-FC incubation showed reduced cytotoxicity (IC50,
B30mM) compared to wells containing the irrelevant isotype
control antibody hu3S193 (IC50, o1m M,P o0.01).
DISCUSSION
Two major obstacles have hampered the progress of ADEPT: the
needs for specific, accessible antigens and for chemically stable
and defined antibody–enzyme constructs of suitable molecular
size. The ADEPT system introduced here is novel regarding the
targeted antigen and the use of a recombinant scFv-based CD
construct.
Incubation of A33-positive tumour cells with this construct
increased 5-FC toxicity by about 300-fold, which was selectively
blocked by preincubation with ‘‘A33scFv-GFP’’, demonstrating
antigen specificity. Neither A33scFv–CD without 5-FC nor a
control construct with 5-FC inhibited cell growth, showing that
specific enzymatic conversion was necessary for cytotoxicity.
Together, these results demonstrate dual (i.e antibody and
enzyme) specificity of the construct and functioning of this
ADEPT system in vitro.
For ADEPT, it is important that CD does not naturally occur in
mammalians, making the enzyme construct the exclusive source of
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Figure 1 Surface Plasmon resonance. Association and dissociation
curves of A33 antibody preparations on an A33 antigen-coated biochip.
The chip was exposed to either the complete huA33 IgG antibody (huA33
IgG), the rabbit-derived single chain fragment (A33scFv) or inclusion body
preparations of the fusion proteins of A33scFv with either cytosine
deaminase (A33scFv–CD IB) or green fluorescent protein (A33scFv–GFP
IB). At 400s, antibody flow was stopped and the chip rinsed with buffer
solution. Protein binding is measured by the refraction of a light beam and
expressed in relative units (RU) over time. The 600s time point and the
relative units at this point are indicated as approximate correlates of affinity.
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Figure 2 A33scFv–CD-mediated cytotoxicity on A33 antigen-positive
vs negative cells: LIM1215 cells and HT29 cells were incubated with a
dilution series of A33scFv–CD fusion protein and, after washing, with the
5-FC prodrug. Survival was measured by the MTT method as described.
A33scFv–CD fusion protein from two different preparations was used on
HT29 cells (m and .) and on LIM1215 cells (K and E). As a control, a
single, high concentration of A33scFv–GFP (&) was used instead of
A33scFv–CD. Mean and s.d. of triplicate samples.
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Figure 3 MTT cytotoxicity blocking assay. As a negative control,
A33scFv–CD was used without subsequent prodrug incubation (’), and
5-FU alone served as positive control (m). In the complete ADEPT assay
with subsequent 5-FC incubation as described in the text, cells were
preincubated either with the ‘‘A33scFv-GFP’’ antibody (E) or with
hu3S193 as an isotypic control antibody (.) for 1h before the fusion
protein was added. Mean and s.d. of triplicate samples.
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sprodrug activation, while allogenic immunogenicity can be
addressed by polyethylene-glycol conjugation with preserved A33
binding (Deckert et al, 2000).
Only recently has the homohexameric structure of bacterial CD
been resolved (Ireton et al, 2002). When the described construct
showed effective dual function, either its monomer has catalytic
activity, or it can form oligomers in solution or after antigen
binding. While the published structure supports monomer activity,
both hypotheses would explain the lower catalytic activity of
A33scFv–CD compared to enzyme alone.
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